title: Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C.
abstract: OBJECTIVE
  Hyperuricemia has been reported as being an adverse effect of pegylated-interferon-alpha2b (Peg-IFNalpha2b) and ribavirin combination therapy for chronic hepatitis C and hyperuricemic changes occur in some patients during the therapy. However, detailed investigation of the elevation of uric acid has not been carried out previously. The incidence and mechanism of hyperuricemia were investigated in this study.
  
  
  METHODS
  The data of 50 patients with chronic hepatitis C who had been treated with Peg-IFNalpha2b and ribavirin combination therapy or pegylated-interferon-alpha2a monotherapy for more than 24 weeks were analyzed. The effects of these treatments were evaluated clinically by the serum uric acid level and its urinary excretion rates.
  
  
  RESULTS
  In patients with pegylated-interferon-alpha2a monotherapy, no significant elevation was shown either in serum uric acid concentrations or excretion rates. On the other hand, serum uric acid concentrations were significantly elevated during the combination therapy, reaching > or =7.0 mg/L in men and > or =6.5 mg/L in women in 15% of patients. The urinary uric acid excretion rate was also elevated significantly.
  
  
  CONCLUSIONS
  Peg-IFNalpha2b plus ribavirin combination therapy induced an elevation of uric acid concentration, although the elevated levels were still within normal limit in many cases. It may be that ribavirin plays a leading role in its elevation and other factors may also be involved.
authors.affiliation: Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Yamashita
authors.forename: Munechika
authors.initials: M
authors.lastname: Enjoji
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kotoh
authors.forename: Masaki
authors.initials: M
authors.lastname: Kato
authors.forename: Akihiro
authors.initials: A
authors.lastname: Ueda
authors.forename: Yuki
authors.initials: Y
authors.lastname: Horikawa
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Tajiri
authors.forename: Nobito
authors.initials: N
authors.lastname: Higuchi
authors.forename: Naoko
authors.initials: N
authors.lastname: Kinukawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Nakamuta
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Takayanagi
mesh_terms: D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D033461:Hyperuricemia / Q000097:blood*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D014527:Uric Acid / Q000097:blood*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014527:Uric Acid; D012254:Ribavirin